Results Preview

Hide All

Participant Flow

Recruitment Details	
Pre-assignment Details	

Arm/Group Title	APR-246 (4.5g/6hr) + PLD	APR-246 (4.5g/3hr) +PLD	APR-246 (4.5g/4hr) +PLD	APR-246 (3.7g/4hr) +PLD	Total (Not public)
Arm/Group Description	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	
Period Title: **Overall Study**					
Started	28	3	2	3	36
Completed	28	3	2	3	36
Not Completed	0	0	0	0	0

Baseline Characteristics

NOTE : A Study Specific Baseline Measure for an Outcome Measure has not been entered.

Arm/Group Title		APR-246 (4.5g/6hr) + PLD	APR-246 (4.5g/3hr) + PLD	APR-246 (4.5g/4hr) + PLD	APR-246 (3.7g/4hr) + PLD	Total
Arm/Group Description		APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	
Overall Number of Baseline Participants		28	3	2	3	**36**
Baseline Analysis Population Description		36 pts with Pt-resistant disease were enrolled, and accumulation of p53 as assessed by immunohistochemistry. Most (69%) patients had 2+ prior lines of therapy. Pts received either a 4.5 g/d of eprenetapopt as a 6-hr IV infusion (78%), or the same or lower dose over 3 or 4 hours (22%) for 4 consecutive days, followed by 40 mg/m2 PLD on Day 4. Based on the safety profile observed, reduced duration infusion regimens with eprenetapopt are feasible.				
Age, Categorical Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	28 participants	3 participants	2 participants	3 participants	36 participants

	<=18 years	0 0%	0 0%	0 0%	0 0%	0 0%
	Between 18 and 65 years	21 75%	2 66.67%	1 50%	2 66.67%	26 72.22%
	>=65 years	7 25%	1 33.33%	1 50%	1 33.33%	10 27.78%
Sex: Female, Male Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	28 participants	3 participants	2 participants	3 participants	36 participants
	Female	28 100%	3 100%	2 100%	3 100%	36 100%
	Male	0 0%	0 0%	0 0%	0 0%	0 0%
Race/Ethnicity, Customized Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	28 participants	3 participants	2 participants	3 participants	36 participants
White		27 96.43%	3 100%	2 100%	3 100%	35 97.22%
Asian		1 3.57%	0 0%	0 0%	0 0%	1 2.78%
Region of Enrollment Measure Type: Number Unit of measure: participants	Number Analyzed	28 participants	3 participants	2 participants	3 participants	36 participants
Belgium		4	0	0	0	4
United Kingdom		3	3	2	3	11
Spain		21	0	0	0	21

Outcome Measures

1. Primary Outcome

Title:	Overall Response Rate (ORR)
Description:	Overall response rate according to RECIST 1.1
Time Frame:	Up to 18 months

Outcome Measure Data

Analysis Population Description

A total of 36 patients were enrolled in this Phase II study. Of the 36 patients, 28 patients were in the main study, 4.5g/6hr dose cohort; 8 patients were in the sub-study as follows: 3 patients were in the 4.5g/3hr dose cohort; 2 patients were in the 4.5g/4hr dose cohort and 3 patients were in the 3.7g/4hr dose cohort.
The 23 Efficacy Evaluable Patients from the Main Study (APR-246 (4.5g/6hr) + PLD) are part of the analysis reported below.

Arm/Group Title	APR-246 (4.5g/6hr) + PLD	APR-246 (4.5g/3hr) + PLD	APR-246 (4.5g/4hr) + PLD	APR-246 (3.7g/4hr) + PLD

▼ Arm/Group Description:		APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion
Overall Number of Participants Analyzed		28	3	2	3
Measure Type: Count of Participants Unit of Measure: participants					
Row Title					
Partial Response (PR)	Number Analyzed	23 participants	0 participants	0 participants	0 participants
		1 4.35%	---	---	---
Stable Disease (SD)	Number Analyzed	23 participants	0 participants	0 participants	0 participants
		15 65.22%	---	---	---
Progressive Disease (PD)	Number Analyzed	23 participants	0 participants	0 participants	0 participants
		7 30.43%	---	---	---
Not Evaluable	Number Analyzed	23 participants	0 participants	0 participants	0 participants
		0 0%	---	---	---
Disease Control Rate (CR+PR+SD)	Number Analyzed	23 participants	0 participants	0 participants	0 participants
		16 69.57%	---	---	---

2. Secondary Outcome

Title:	Incidence of Treatment-emergent Adverse Events With Combined APR-246 and PLD Regimen
▼ Description:	Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. AEs were graded according to NCI CTCAE (Version 4.0). Patients with multiple TEAEs were only counted once within a summary category: SOC, PT, maximum grade, or relationship to treatment. Patients with events in more than one category were counted once within each category.
Time Frame:	Until 30 days after the last administration of study treatment to the patient

▼ Outcome Measure Data ✓

▼ Analysis Population Description
[Not specified]

Arm/Group Title	APR-246 (4.5g/6hr) + PLD	APR-246 (4.5g/3hr) + PLD	APR-246 (4.5g/4hr) + PLD	APR-246 (3.7g/4hr) + PLD
▼ Arm/Group Description:	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion
Overall Number of Participants Analyzed	28	3	2	3
Measure Type: Count of Participants Unit of Measure: participants				
Row Title				

With Any Treatment-Emergent Adverse Events (TEAEs)	28	100%	3	100%	2	100%	3	100%
With APR-246 Related TEAEs	25	89.29%	3	100%	2	100%	3	100%
With PLD Related TEAEs	24	85.71%	3	100%	2	100%	3	100%
With Severity Grade >=3	14	50%	3	100%	2	100%	3	100%
With Severity Grade >=3 APR-246 Related TEAEs	6	21.43%	2	66.67%	2	100%	2	66.67%
With Severity Grade >=3 PLD Related TEAEs	7	25%	2	66.67%	0	0%	2	66.67%
With Any Serious AEs	11	39.29%	1	33.33%	1	50%	2	66.67%
With Any Serious, APR-246 Related AEs	4	14.29%	1	33.33%	1	50%	1	33.33%
With Any Serious, PLD Related AEs	2	7.14%	1	33.33%	0	0%	1	33.33%
Who Discontinued APR-246 Due to TEAEs	2	7.14%	1	33.33%	0	0%	0	0%
Who Discontinued PLD Due to TEAEs	0	0%	0	0%	0	0%	0	0%
Who Died Due to any TEAEs	0	0%	0	0%	0	0%	0	0%

Adverse Events

Time Frame	TEAEs were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose.
Adverse Event Reporting Description	AEs were graded according to NCI CTCAE (Version 4.0).
Source Vocabulary Name for Table Default	MedDRA (17.1)
Collection Approach for Table Default	Systematic Assessment

Arm/Group Title	APR-246 (4.5g/6hr) + PLD	APR-246 (4.5g/3hr) + PLD	APR-246 (4.5g/4hr) + PLD	APR-246 (3.7g/4hr) + PLD
▼ Arm/Group Description	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion	APR-246: Intravenous infusion Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion

All-Cause Mortality

	APR-246 (4.5g/6hr) + PLD	**APR-246 (4.5g/3hr) + PLD**	**APR-246 (4.5g/4hr) + PLD**	**APR-246 (3.7g/4hr) + PLD**
	Affected / at Risk (%)	Affected / at Risk (%)	Affected / at Risk (%)	Affected / at Risk (%)
Total	9/28 (32.14%)	1/3 (33.33%)	0/2 (0%)	1/3 (33.33%)

▼ **Serious Adverse Events**

	APR-246 (4.5g/6hr) + PLD	**APR-246 (4.5g/3hr) + PLD**	**APR-246 (4.5g/4hr) + PLD**	**APR-246 (3.7g/4hr) + PLD**

	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	11/28 (39.29%)		1/3 (33.33%)		1/2 (50%)		2/3 (66.67%)	
Blood and lymphatic system disorders								
Thrombocytopenia † A	0/28 (0%)	0	1/3 (33.33%)	6	0/2 (0%)	0	0/3 (0%)	0
Gastrointestinal disorders								
Intestinal obstruction † A	3/28 (10.71%)	3	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Nausea † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Peritoneal fibrosis † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Small intestinal obstruction † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Vomiting † A	1/28 (3.57%)	2	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
General disorders								
Mucosal inflammation † A	1/28 (3.57%)	3	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Infections and infestations								
Device related infection † A	0/28 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.33%)	1
Infection † A	0/28 (0%)	0	1/3 (33.33%)	1	0/2 (0%)	0	1/3 (33.33%)	1
Respiratory tract infection † A	0/28 (0%)	0	0/3 (0%)	0	0/2 (0%)	0	1/3 (33.33%)	2
Upper respiratory tract infection † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Urinary tract infection † A	0/28 (0%)	0	1/3 (33.33%)	2	0/2 (0%)	0	0/3 (0%)	0
Injury, poisoning and procedural complications								
Lumbar vertebral fracture † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Procedural pain † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Musculoskeletal and connective tissue disorders								
Arthralgia † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Nervous system disorders								
Ataxia † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0
Dizziness † A	0/28 (0%)	0	0/3 (0%)	0	1/2 (50%)	2	0/3 (0%)	0
Renal and urinary disorders								
Renal failure † A	1/28 (3.57%)	1	0/3 (0%)	0	0/2 (0%)	0	0/3 (0%)	0

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA (17.1)

▼ Other (Not Including Serious) Adverse Events

Frequency Threshold for Reporting Other Adverse Events	5%			
	APR-246 (4.5g/6hr) + PLD	**APR-246 (4.5g/3hr) + PLD**	**APR-246 (4.5g/4hr) + PLD**	**APR-246 (3.7g/4hr) + PLD**

	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	28/28 (100%)		3/3 (100%)		2/2 (100%)		3/3 (100%)	
Blood and lymphatic system disorders								
Anemia † A	6/28 (21.43%)		1/3 (33.33%)		1/2 (50%)		1/3 (33.33%)	
Hypophosphatemia † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		1/3 (33.33%)	
Neutropenia † A	4/28 (14.29%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	
Thrombocytopenia † A	0/28 (0%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	
Ear and labyrinth disorders								
Ear and labyrinth disorders † A	1/28 (3.57%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	
Eye disorders								
Blepharitis † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		1/3 (33.33%)	
Lacrimation increased † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		1/3 (33.33%)	
Gastrointestinal disorders								
Abdominal distension † A	3/28 (10.71%)		0/3 (0%)		0/2 (0%)		0/3 (0%)	
Abdominal pain † A	9/28 (32.14%)		0/3 (0%)		1/2 (50%)		3/3 (100%)	
Ascites † A	2/28 (7.14%)		0/3 (0%)		0/2 (0%)		0/3 (0%)	
Constipation † A	11/28 (39.29%)		1/3 (33.33%)		0/2 (0%)		2/3 (66.67%)	
Diarrhea † A	6/28 (21.43%)		0/3 (0%)		0/2 (0%)		2/3 (66.67%)	
Dry mouth † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		1/3 (33.33%)	
Dyspepsia † A	1/28 (3.57%)		0/3 (0%)		0/2 (0%)		1/3 (33.33%)	
Dysphagia † A	0/28 (0%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	
Gastric ulcer † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		1/3 (33.33%)	
Gastroesophageal reflux disease † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		2/3 (66.67%)	
Haemorrhoids † A	2/28 (7.14%)		0/3 (0%)		0/2 (0%)		0/3 (0%)	
Intestinal obstruction † A	2/28 (7.14%)		0/3 (0%)		0/2 (0%)		0/3 (0%)	
Nausea † A	17/28 (60.71%)		2/3 (66.67%)		1/2 (50%)		3/3 (100%)	
Stomatitis † A	1/28 (3.57%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	
Vomiting † A	12/28 (42.86%)		2/3 (66.67%)		2/2 (100%)		3/3 (100%)	
General disorders								
Asthenia † A	10/28 (35.71%)		0/3 (0%)		0/2 (0%)		0/3 (0%)	
Device occlusion † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		2/3 (66.67%)	
Edema peripheral † A	4/28 (14.29%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	
Fatigue † A	6/28 (21.43%)		3/3 (100%)		1/2 (50%)		3/3 (100%)	
Gait disturbance † A	2/28 (7.14%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	
Infusion site vesicles † A	0/28 (0%)		0/3 (0%)		0/2 (0%)		1/3 (33.33%)	
Mucosal inflammation † A	7/28 (25%)		1/3 (33.33%)		0/2 (0%)		1/3 (33.33%)	
Pyrexia † A	2/28 (7.14%)		0/3 (0%)		0/2 (0%)		0/3 (0%)	
Immune system disorders								
Hypersensitivity † A	1/28 (3.57%)		1/3 (33.33%)		0/2 (0%)		0/3 (0%)	

Infections and infestations				
Conjunctivitis † A	2/28 (7.14%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Device related infection † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Infection † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	1/3 (33.33%)
Lip infection † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Respiratory tract infection † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Urinary tract infection † A	3/28 (10.71%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Injury, poisoning and procedural complications				
Vascular access complication † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Investigations				
Glomerular filtration rate decreased † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Metabolism and nutrition disorders				
Decreased appetite † A	7/28 (25%)	1/3 (33.33%)	1/2 (50%)	3/3 (100%)
Hypoalbuminemia † A	1/28 (3.57%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Musculoskeletal and connective tissue disorders				
Arthralgia † A	2/28 (7.14%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Back pain † A	4/28 (14.29%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Muscular weakness † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	1/3 (33.33%)
Musculoskeletal chest pain † A	1/28 (3.57%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Neck pain † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Pain in extremity † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Nervous system disorders				
Akathisia † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Aphasia † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Apraxia † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Ataxia † A	2/28 (7.14%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Balance disorder † A	0/28 (0%)	1/3 (33.33%)	1/2 (50%)	0/3 (0%)
Dizziness † A	5/28 (17.86%)	1/3 (33.33%)	2/2 (100%)	1/3 (33.33%)
Dysarthria † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Dysgeusia † A	3/28 (10.71%)	1/3 (33.33%)	0/2 (0%)	1/3 (33.33%)
Dyskinesia † A	1/28 (3.57%)	1/3 (33.33%)	0/2 (0%)	1/3 (33.33%)
Headache † A	2/28 (7.14%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Neuropathy peripheral † A	1/28 (3.57%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Nystagmus † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Paresthesia † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Peripheral sensory neuropathy † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Somnolence † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	1/3 (33.33%)
Tremor † A	0/28 (0%)	2/3 (66.67%)	0/2 (0%)	0/3 (0%)

Psychiatric disorders				
Confusional state † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Hallucination † A	0/28 (0%)	1/3 (33.33%)	1/2 (50%)	1/3 (33.33%)
Insomnia † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Irritability † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Nightmare † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Renal and urinary disorders				
Micturition urgency † A	0/28 (0%)	0/3 (0%)	1/2 (50%)	0/3 (0%)
Renal impairment † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Respiratory, thoracic and mediastinal disorders				
Cough † A	3/28 (10.71%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Dyspnea † A	5/28 (17.86%)	0/3 (0%)	0/2 (0%)	0/3 (0%)
Pulmonary embolism † A	2/28 (7.14%)	0/3 (0%)	0/2 (0%)	0/3 (0%)
Skin and subcutaneous tissue disorders				
Alopecia † A	2/28 (7.14%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Dry skin † A	2/28 (7.14%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Miliaria † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Palmar-plantar erythrodysesthesia syndrome † A	1/28 (3.57%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Pruritus † A	0/28 (0%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Rash † A	2/28 (7.14%)	0/3 (0%)	0/2 (0%)	1/3 (33.33%)
Rash maculo-papular † A	0/28 (0%)	1/3 (33.33%)	0/2 (0%)	0/3 (0%)
Vascular disorders				
Vascular disorders † A	3/28 (10.71%)	0/3 (0%)	0/2 (0%)	0/3 (0%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA (17.1)

Limitations and Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

Name/Official Title: Dr Eyal C Attar, SVP & CMO
Organization: Aprea Therapeutics

Phone: +1 617 804 6947
Email: Eyal.Attar@Aprea.com